Aquestive Therapeutics
AQST
97 hedge funds and large institutions have $110M invested in Aquestive Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 31 closing their positions.
188% more call options, than puts
Call options by funds: $1.9M | Put options by funds: $661K
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
0.55% more ownership
Funds ownership: 46.12% → 46.67% (+0.55%)
0% more funds holding
Funds holding: 97 → 97 (0)
0% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 31
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $177M → $110M (-$66.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.7M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.29M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.68M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$6.58M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$4.26M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$2.99M |
| 4 |
Renaissance Technologies
New York
|
-$2.94M |
| 5 |
ACM
Altium Capital Management
New York
|
-$2.83M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CFD
126
Creative Financial Designs
Kokomo,
Indiana
| – | -$2.98K | -700 | Closed |
|
|
HT
127
Headlands Technologies
Chicago,
Illinois
| – | -$1.15K | -269 | Closed |
|
128
T. Rowe Price Associates
Baltimore,
Maryland
| – | +$79.7K | +23,848 | New |
|
AQST Hedge Fund Activity: Q2 2024 in Review
97 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2024, worth a combined $110M — down 37% from $177M a quarter earlier.
Fund positioning in AQST was balanced in Q2 2024: 31 funds opened new positions, 31 closed out, 31 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $13.7M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $6.58M sold.
- 97 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $110M of Aquestive Therapeutics stock for Q2 2024, down 37% quarter-over-quarter.
- 31 funds opened new Aquestive Therapeutics positions in Q2 2024 and 31 closed out, a net change of 0 holders.
- The largest Aquestive Therapeutics buyer in Q2 2024 was BlackRock, an estimated $13.7M added.
- The largest Aquestive Therapeutics seller in Q2 2024 was Laurion Capital Management, an estimated $6.58M sold.
Based on aggregated 13F filings for Q2 2024.